Correction: Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine Versus Nimenrix in Healthy Adolescents: A Randomized Phase IIIb Multicenter Study

Correction: Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine Versus Nimenrix in Healthy Adolescents: A Randomized Phase IIIb Multicenter Study

Saved in:

Bibliographic Details
Main Authors:	Javier Díez-Domingo, Róbert Simkó, Giancarlo Icardi, Chan Poh Chong, Céline Zocchetti, Olga Syrkina, Siham Bchir, Isabelle Bertrand-Gerentes
Format:	Article
Language:	English
Published:	Adis, Springer Healthcare 2025-04-01
Series:	Infectious Diseases and Therapy
Online Access:	https://doi.org/10.1007/s40121-025-01150-1
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine Versus Nimenrix in Healthy Adolescents: A Randomized Phase IIIb Multicenter Study
by: Javier Díez-Domingo, et al.
Published: (2024-07-01)

Five-Year Immune Persistence of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) and Immunogenicity and Safety of a Booster Dose in Children
by: Federico Martinón-Torres, et al.
Published: (2025-04-01)

Modeling antibody persistence after MenACYW-TT vaccination and comparative analysis with other quadrivalent meningococcal vaccines
by: Laurent Coudeville, et al.
Published: (2025-07-01)

An overview of the meningococcal disease and impact of the quadrivalent meningococcal conjugate vaccine
by: Asmaa Alrobai, et al.
Published: (2021-12-01)

Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) Administered with Routine Pediatric Vaccines: A European Randomized Controlled Trial
by: Federico Martinon-Torres, et al.
Published: (2025-07-01)

Safety and Immunogenicity of Two Doses of Quadrivalent Meningococcal Conjugate Vaccine or One Dose of Meningococcal Group C Conjugate Vaccine, both Administered Concomitantly with Routine Immunization to 12- to 18-Month-Old Children
by: Francisco Noya, et al.
Published: (2014-01-01)

A new quadrivalent meningococcal tetanus toxoid conjugate vaccine: Menquadfi® (MENACWY-TT)
by: Ener Cagri Dinleyici, et al.
Published: (2025-12-01)

Immunogenicity and Safety of a Quadrivalent Meningococcal Tetanus Toxoid-Conjugate Vaccine (MenACYW-TT) Administered Concomitantly with Pneumococcal Conjugate Vaccine in Healthy Toddlers in the Russian Federation: a Phase III Randomized Study
by: L. S. Namazova-Baranova, et al.
Published: (2023-01-01)

Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine (MenACWY-D) in Children 9–23 Months of Age in Russian Federation: Results of Russian Part of International Study in Russia and India
by: O. A. Perminova, et al.
Published: (2020-05-01)

Assessment of Reactogenicity and Immunogenicity of the Quadrivalent Live Attenuated Influenza Vaccine
by: D. A. Lioznov, et al.
Published: (2018-06-01)

Immune persistence and booster response of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) 5 years after primary vaccination of adults at ≥56 years of age
by: Corwin A. Robertson, et al.
Published: (2024-12-01)

Meningococcal disease. Meningococcal conjugate polysaccharide vaccines and new generation vaccines. Report 3
by: M. V. Abramtseva, et al.
Published: (2018-02-01)

Immunogenicity and safety of meningococcal vaccines, MenACWY-CRM and 4CMenB, in groups at increased risk for meningococcal disease
by: Shravani Bobde, et al.
Published: (2025-12-01)

Further Insights into the Measurement of Free Polysaccharide in Meningococcal Conjugate Vaccines
by: Nicola J. Beresford, et al.
Published: (2025-02-01)

Evaluation of Haemophilus influenzae Type B Conjugate Vaccine (Meningococcal Protein Conjugate) in Canadian Infants
by: David W Scheifele, et al.
Published: (1994-01-01)

The immunogenicity and safety of an investigational meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (ACWY-TT) compared with a licensed meningococcal tetravalent polysaccharide vaccine<subtitle>A randomized, controlled non-inferiority study</subtitle>
by: Ghassan Dbaibo, et al.
Published: (2012-07-01)

Distinct binding and immunogenic properties of the gonococcal homologue of meningococcal factor h binding protein.
by: Ilse Jongerius, et al.
Published: (2013-01-01)

The immunogenicity and safety of an inactivated quadrivalent influenza vaccine and a 23-valent pneumococcal polysaccharide vaccine in individuals with chronic diseases
by: Wanqin Tang, et al.
Published: (2025-08-01)

Correction: The immunogenicity and safety of an inactivated quadrivalent influenza vaccine and a 23-valent pneumococcal polysaccharide vaccine in individuals with chronic diseases
by: Frontiers Production Office
Published: (2025-08-01)

Quadrivalent HPV (4vHPV) vaccine immunogenicity and safety in women using immunosuppressive drugs due to solid organ transplant
by: Karina Takesaki Miyaji, et al.
Published: (2024-11-01)

Analytical Challenges in Novel Pentavalent Meningococcal Conjugate Vaccine (A, C, Y, W, X)
by: Pankaj Sharma, et al.
Published: (2024-10-01)

Safety and Immunogenicity of Meningococcal Groups A and C Polysaccharide Vaccine in Adults 18–60 years of age
by: V. V. Romanenko, et al.
Published: (2023-11-01)

Neurodegeneration and aging pathways in Mucopolysaccharidosis IIIB
by: Yorran Hardman Araújo Montenegro
Published: (2025-07-01)

An Evaluation of the Safety, Immunogenicity, and Protective Efficacy of a Combined Diphtheria–Tetanus–Acellular Pertussis, <i>Haemophilus influenzae</i> Type b, and ACYW135 Meningococcal Conjugate Vaccine in Murine and Rat Models
by: Xiuwen Sui, et al.
Published: (2025-07-01)

The investigational meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (ACWY-TT) and the seasonal influenza virus vaccine are immunogenic and well-tolerated when co-administered in adults
by: Mari Rose Aplasca-De Los Reyes, et al.
Published: (2012-07-01)

Meningococcal Urethritis: an additional Source of Meningococcal Disease?
by: N. N. Kostyukova, et al.
Published: (2020-07-01)

The 13-year long-term follow-up on the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in Chinese females vaccinated at 20–45 years of age
by: Tianmeng Wen, et al.
Published: (2024-12-01)

Immunogenicity and safety of concomitant administration of recombinant COVID-19 vaccine and quadrivalent inactivated influenza vaccine in Chinese adults: An open-label, randomized, controlled trial
by: Tao Huang, et al.
Published: (2024-12-01)

Immunogenicity and Antibody Persistence of the Inactivated Quadrivalent Influenza Vaccine in Pediatric Patients Post-Chemotherapy or Allogeneic Hematopoietic Stem Cell Transplantation Versus Healthy Controls
by: Mi Yeon Hur, et al.
Published: (2024-10-01)

Safety and immunogenicity of full-dose quadrivalent influenza vaccine in children 6–35 months of age in China: A randomized, double-blind, clinical trial
by: Shilei Wang, et al.
Published: (2024-12-01)

Storage Conditions of Conjugated Reagents Can Impact Results of Immunogenicity Assays
by: Robert J. Kubiak, et al.
Published: (2016-01-01)

Immunogenicity and safety of 1 versus 2 doses of quadrivalent-inactivated influenza vaccine in children aged 3–8 years with or without previous influenza vaccination histories
by: Feng Wen, et al.
Published: (2025-12-01)

The Safety of 4-valent Meningococcal Conjugate Vaccine in Two Years Old Children: Prospective Cohort Study in Sakhalin Region
by: Oxana V. Solonina, et al.
Published: (2019-09-01)

Immunogenicity and Safety of 13-valent Conjugated Pneumococcal Vaccine in Patients with Rheumatoid Arthritis
by: B. T. Batozhargalova, et al.
Published: (2024-03-01)

Safety, tolerability, and immunogenicity of pentavalent meningococcal MenABCWY vaccine in healthy infants: A phase 2b randomized clinical trial
by: Federico Martinon-Torres, et al.
Published: (2025-12-01)

Invasive meningococcal disease
by: Vanessa L. Strelow, et al.
Published: (2013-09-01)

Outcomes of combination therapy for stage IIA–IIIB cervical cancer
by: D. K. Reyes Santiago, et al.
Published: (2019-02-01)

Monteggia fracture associated with olecranon fracture-dislocation Mayo IIIB
by: Maljković Filip, et al.
Published: (2025-01-01)

The Safety and Immunogenicity of a Quadrivalent Influenza Subunit Vaccine in Healthy Children Aged 6–35 Months: A Randomized, Blinded and Positive-Controlled Phase III Clinical Trial
by: Lili Huang, et al.
Published: (2025-04-01)

Cost-effectiveness of quadrivalent human papillomavirus vaccination in adolescent girls
by: A. V. Rudakova, et al.
Published: (2016-11-01)